Maintenance of Platelet Inhibition With Cangrelor After Discontinuation of Thienopyridines in Patients Undergoing Surgery - BRIDGE


The goal of the trial was to evaluate treatment with cangrelor, an intravenous P2Y12 inhibitor (plasma half-life of 3-6 minutes), compared with placebo among patients required to stop thienopyridine therapy due to need for cardiac surgery.